Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
FDA approves Rextovy, a new OTC naloxone nasal spray, broadening access to opioid overdose reversal medication as part of the Great American Recovery Initiative.
University of Southern California receives funding to launch its first clinical study of psilocybin-assisted therapy combined with mindfulness meditation for mental well-being.
Columbia County, New York releases its first comprehensive report tracking opioid settlement funds, revealing declining annual payments and detailed spending priorities for addiction treatment.
Rhode Island overdose deaths fell to 219 in 2025, a 50% decline from 2022, surpassing the state's 2030 reduction goal. Learn how harm reduction and naloxone distribution contributed.
For the first time since 2013, Massachusetts recorded fewer than 1,000 opioid-related overdose deaths in 2025, marking a nearly 60% decline from the 2022 peak.
A new federal Request for Information invites patients, providers and researchers to tell HHS which addiction programs work — with comments due July 5, 2026.
A randomized quadruple-blind trial found psilocybin-assisted therapy achieved 30% complete abstinence at 180 days vs 0% with placebo, with 72% reduced relapse risk.
Baltimore County unveils a transparent online dashboard allowing residents to monitor how opioid settlement funds are being used to combat the addiction crisis.
New UCLA research finds that California adolescents using drugs or alcohol face triple the suicide risk, with nearly half experiencing serious psychological distress.